Wheler, Jennifer

A phase I first-in-human trial of bardoxolone methyl in patients with advanced solid tumors and lymphomas

Hong, D. S., Kurzrock, R., Supko, J. G., He, X., Naing, A., Wheler, J., Lawrence, D., Eder, J. P., Meyer, C. J., Ferguson, D. A., et al. (2012) · Clinical Cancer Research

Genomics, phytochemicals, and oxidative stressBioactive Compounds and Antitumor Agents

Cited by 236

Safety, pharmacokinetics, and activity of EZN‐2208, a novel conjugate of polyethylene glycol and SN38, in patients with advanced malignancies

Kurzrock, R., Goel, S., Wheler, J., Hong, D., Fu, S., Rezai, K., Morgan‐Linnell, S. K., Urien, S., Mani, S., Chaudhary, I., et al. (2012) · Cancer

Cancer therapeutics and mechanismsPharmacogenetics and Drug Metabolism

Cited by 50

Combining Erlotinib and Cetuximab Is Associated with Activity in Patients with Non–Small Cell Lung Cancer (Including Squamous Cell Carcinomas) and Wild-Type EGFR or Resistant Mutations

Wheler, J. J., Tsimberidou, A. M., Falchook, G. S., Zinner, R. G., Hong, D. S., Fok, J. Y., Fu, S., Piha-Paul, S. A., Naing, A., & Kurzrock, R. (2013) · Molecular Cancer Therapeutics

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 34

Molecular determinants of drug-specific sensitivity for epidermal growth factor receptor (EGFR) exon 19 and 20 mutants in non-small cell lung cancer

Tsigelny, I. F., Wheler, J. J., Greenberg, J. P., Kouznetsova, V. L., Stewart, D. J., Bazhenova, L., & Kurzrock, R. (2015) · Oncotarget

Lung Cancer Treatments and MutationsHER2/EGFR in Cancer Research

Cited by 30

Revisiting Clinical Trials Using EGFR Inhibitor-Based Regimens in Patients with Advanced Non-Small Cell Lung Cancer: A Retrospective Analysis of an MD Anderson Cancer Center Phase I Population

Wheler, J., Falchook, G., Tsimberidou, A. M., Hong, D., Naing, A., Piha-Paul, S., Chen, S. S., Heymach, J., Fu, S., Stephen, B., et al. (2013) · Oncotarget

Lung Cancer Treatments and MutationsLung Cancer Diagnosis and Treatment

Cited by 17